Immunovant

IMVTNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$8.246 B

$39.95 +0.53%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

-$505.6M

Loss-making

Shares outstanding

206,552,682

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#16QiagenQGEN$8.72B
#17VaxcytePCVX$8.64B
#18ImmunovantIMVT$8.25B
#19ImmunityBioIBRX$8.10B
#20Twist BioscienceTWST$7.25B

Where these numbers come from

Share counts and financials for Immunovant are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.